125 related articles for article (PubMed ID: 3220081)
1. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1835-7. PubMed ID: 3220081
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
3. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
4. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1992 Jun; 45(3):323-8. PubMed ID: 1612511
[TBL] [Abstract][Full Text] [Related]
5. Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer.
Aravantinos D; Michalas S; Papazefkos V; Christoforaki M; Stypsaneli A; Vlachos G; Athanasiadis P
Eur J Obstet Gynecol Reprod Biol; 1990 Dec; 37(3):265-70. PubMed ID: 2227069
[TBL] [Abstract][Full Text] [Related]
6. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
7. Value of serum 125Ca levels: does the result preclude second look?
Potter ME; Moradi M; To AC; Hatch KD; Shingleton HM
Gynecol Oncol; 1989 May; 33(2):201-3. PubMed ID: 2703182
[TBL] [Abstract][Full Text] [Related]
8. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
9. CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
Berek JS; Knapp RC; Malkasian GD; Lavin PT; Whitney C; Niloff JM; Bast RC
Obstet Gynecol; 1986 May; 67(5):685-9. PubMed ID: 3457330
[TBL] [Abstract][Full Text] [Related]
10. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
12. Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125.
Mogensen O; Mogensen B; Jakobsen A
Cancer; 1989 Nov; 64(9):1867-71. PubMed ID: 2477138
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer.
Benedetti Panici P; Scambia G; Baiocchi G; Iacobelli S; Mancuso S
Gynecol Oncol; 1989 Dec; 35(3):286-9. PubMed ID: 2599461
[TBL] [Abstract][Full Text] [Related]
14. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas.
Barrenetxea G; Martin-Mateos M; Barzazan MJ; Montoya F; Matia JC; Rodriguez-Escudero FJ
Eur J Gynaecol Oncol; 1990; 11(5):369-74. PubMed ID: 2097153
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
Rubin SC; Hoskins WJ; Hakes TB; Markman M; Reichman BS; Chapman D; Lewis JL
Am J Obstet Gynecol; 1989 Mar; 160(3):667-71. PubMed ID: 2648838
[TBL] [Abstract][Full Text] [Related]
18. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Apr; 37(1):44-6. PubMed ID: 2323611
[TBL] [Abstract][Full Text] [Related]
20. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma.
Rose PG; Terrien JM; Baker S
J Surg Oncol; 1994 Jul; 56(3):168-71. PubMed ID: 8028348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
